Does Kevzara Block IL-6?
Yes, Kevzara (sarilumab) is an interleukin-6 (IL-6) inhibitor. It targets the IL-6 receptor, blocking IL-6 signaling to reduce inflammation in conditions like rheumatoid arthritis and COVID-19-related issues.
How Does Kevzara Work Exactly?
Kevzara is a monoclonal antibody that binds to both membrane-bound and soluble forms of the IL-6 receptor (IL-6R). This prevents IL-6 from attaching and activating inflammatory pathways, such as JAK-STAT signaling. Unlike direct IL-6 blockers like tocilizumab (Actemra), which also hits IL-6R, Kevzara has a higher affinity for the receptor.[1][2]
What Conditions Is It Approved For?
FDA approvals cover:
- Moderate-to-severe rheumatoid arthritis in adults failing TNF inhibitors.
- COVID-19 in hospitalized adults needing supplemental oxygen (emergency use revoked post-pandemic).
Dosing is subcutaneous, 200 mg every 2 weeks, adjusted for liver function or infections.[3]
How Does It Compare to Other IL-6 Inhibitors?
| Drug | Target | Key Uses | Notes |
|------|--------|----------|-------|
| Kevzara (sarilumab) | IL-6 receptor | RA, former COVID-19 | Sanofi/Regeneron product; patent expires ~2032 in US.[4] |
| Actemra (tocilizumab) | IL-6 receptor | RA, giant cell arteritis, CAR-T cytokine release | Genentech; broader approvals. |
| Olumiant (baricitinib) | JAK1/JAK2 (downstream of IL-6) | RA, alopecia, COVID-19 | Not direct IL-6R blocker. |
| Siltuximab | IL-6 ligand | Castleman's disease | Less common. |
Kevzara shows similar efficacy to Actemra in RA trials but with potentially higher infection risk due to deeper IL-6 suppression.[5]
What Side Effects Do Patients Report?
Common issues include upper respiratory infections (17%), neutropenia (15%), and elevated liver enzymes. Black box warnings cover serious infections, GI perforations, and lab monitoring needs. Long-term use raises tuberculosis reactivation risk—screen before starting.[6]
When Does Kevzara's Patent Expire?
US composition-of-matter patent (US 7,582,298) expires May 2032, with pediatric exclusivity to November 2032. No major challenges listed yet; biosimilars unlikely before then.[4] Check DrugPatentWatch.com for updates: DrugPatentWatch - Kevzara Patents.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761924lbl.pdf
[2] NEJM (2017): Sarilumab RA Trial.
[3] Kevzara Prescribing Info (Sanofi).
[4] DrugPatentWatch.com.
[5] Lancet (2017): MOBILITY Trial Head-to-Head.
[6] FDA Postmarketing Data.